Trials / Conditions / Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Squamous Cell Carcinoma of the Head and Neck (SCCHN)

12 registered clinical trials studyying Squamous Cell Carcinoma of the Head and Neck (SCCHN).

Status	Trial	Sponsor	Phase
Active Not Recruiting	A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies NCT06974734	Pfizer	Phase 1
Completed	Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC NCT05057247	Glenn J. Hanna	Phase 2
Terminated	Study of INCA 0186 in Subjects With Advanced Solid Tumors NCT04989387	Incyte Corporation	Phase 1
Terminated	Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tu NCT04052204	Pfizer	Phase 1 / Phase 2
Completed	Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastati NCT03405142	Eben Rosenthal	Phase 2
Completed	A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies NCT03538028	Incyte Biosciences International Sàrl	Phase 1
Completed	Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer NCT02499120	Pfizer	Phase 2
Completed	A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced R NCT02335918	Celldex Therapeutics	Phase 1 / Phase 2
Completed	Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors NCT02001623	Seagen Inc.	Phase 1 / Phase 2
Completed	Study of PX-866 and Docetaxel in Solid Tumors NCT01204099	Cascadian Therapeutics Inc.	Phase 1 / Phase 2
Terminated	A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck NCT01285635	University of Michigan Rogel Cancer Center	Phase 2
Terminated	Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck NCT00392665	Massachusetts General Hospital	Phase 2